One-Day TMS for Depression (Free 15-Min Consultation)

iTBS format: ONE-D uses repeated blocks of intermittent Theta Burst Stimulation (iTBS). Each iTBS block is brief, but the full 20-session schedule builds a cumulative neuroplastic effect.

High density, short intervals: Repeats many short sessions with short rest periods; the accumulated stimulation aims to produce a stronger, faster biological shift.

Optional augmentation: In some protocols, clinicians add pharmacologic agents (e.g., D-cycloserine, short-acting stimulants) to enhance plasticity — always under careful psychiatric supervision and informed consent.

Individualized mapping & monitoring: Motor-threshold mapping and personalized targeting are used before the session so stimulation is safe and tailored to you.

Reimagining TMS: The AMPA Cap and Accelerated Protocols

The AMPA Cap is more than a hardware upgrade - its dual-coil design (one for surface stimulation, one for deeper midline structures) allows for highly accurate causal network mapping and access to multiple prefrontal sub-targets (DLPFC, DMPFC, rOFC). This expanded reach and precision are particularly valuable for single-day neuroplastogen-enhanced TMS, where exact targeting and reproducibility matter most. Early clinical data show strong response/remission rates with AMPA-augmented, single-day protocols.

Why it matters: AMPA Cap → better targeting → more consistent delivery of intensive stimulation, which may increase the likelihood of a meaningful response in compressed protocols.

Option	Sessions	Typical timing	Insurance
Standard TMS	36+	4–8 weeks (1/day)	Often covered
5-day Accelerated TMS	50	5 days (10/day)	Often self-pay ($7000)
ONE-D	20	1–2 days	Generally self-pay ($3,000)

Several pilot and case-series reports on highly accelerated, neuroplastogen-enhanced protocols report high early response/remission rates (for example, single-day/accelerated protocols with up to ~90% response and ~74% remission in some case series at 6–12 weeks). These are promising early results; large randomized trials and longer-term follow-up remain an area of active study.

Accelerated protocols such as 50 sessions in 5 days (SAINT-style) demonstrated strong outcomes in trials and real-world clinic experience; ONE-D builds on that paradigm by intensifying delivery while preserving physician oversight and mapping.